Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
single dose · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK1144814 | EXPERIMENTAL | Subjects will receive either GSK1144814 or placebo at each treatment arm. |
| placebo | PLACEBO_COMPARATOR | Subjects will receive either GSK1144814 or placebo at each treatment arm. |
| placebo arm | PLACEBO_COMPARATOR | There are single dose treatment arms of GSK561679, lorazepam as well as placebo. |
| GSK561679 arm | EXPERIMENTAL | There are single dose treatment arms of GSK561679, lorazepam as well as placebo. |
| lorazepam arm | ACTIVE_COMPARATOR | There are single dose treatment arms of GSK561679, lorazepam as well as placebo. |
| Name | Type | Description |
|---|---|---|
| single dose | DRUG | Subjects will receive a single dose of GSK1144814 or placebo. |
Inclusion Criteria: * Healthy male and female * Body weight 50 kg or higher and BMI within the range 19 - 29.9 kg/m2 * Willing to use appropriate contraception methods Exclusion Criteria: * Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody result * Any serious medical disorder or ...
GSK561679 is an investigational drug being studied for use in depressive disorder and anxiety disorders. It was evaluated in a Phase 1 clinical trial in healthy volunteers to investigate its effects on brain activation during emotional processing. The drug is still in clinical development and has not been approved by regulatory authorities.
GSK561679 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company conducted Phase 1 clinical trials to study the drug's effects in healthy volunteers and its potential use in psychiatric conditions such as depressive disorder and anxiety disorders.
GSK561679 is in Phase 1 clinical development. It has completed Phase 1 trials, including a study on brain activation during emotional processing in healthy volunteers. As an investigational drug, it is not yet approved and remains in early-stage clinical testing.
GSK561679 has been studied in Phase 1 clinical trials, including NCT00513565, which examined its effects on brain activation during emotional processing in healthy volunteers with depressive disorder and anxiety disorders. This trial was completed in the United States with 22 female participants.
GSK561679 is not the same as Paxil CR or Secotex. Paxil CR (paroxetine) and Secotex (tamsulosin) are separate drugs studied in bioequivalence trials listed alongside GSK561679 in the same developer's portfolio. GSK561679 is a distinct investigational compound with its own clinical development program.